(Q53389588)

13 May 2018

title

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. (English)

1 reference

13 May 2018

1 reference

Ingo Stammberger

1

1 reference

13 May 2018

Axel Bube

2

1 reference

13 May 2018

Beate Durchfeld-Meyer

3

1 reference

13 May 2018

Hans Donaubauer

4

1 reference

13 May 2018

Gotz Troschau

5

1 reference

13 May 2018

publication date

1 May 2002

1 reference

13 May 2018

International Journal of Toxicology

published in

1 reference

13 May 2018

volume

21

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

171-179

1 reference

13 May 2018

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Subcutaneous sarcoma as an index of carcinogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Spontaneous fibrous histiocytic neoplasms in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

Spontaneous Skin Neoplasms in Aged Sprague-Dawley Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10915810290096306

10.1080/10915810290096306

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018